PTGXProtagonist Therapeutics, Inc同业对比
Protagonist Therapeutics, Inc 与SPDR S&P Biotech ETF 持仓的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:XBI 前十大持仓| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTGX本股 | $9.2B#6 | 138.0x#1 | 10.9x#9 | 199.9x#5 | -89.4%#8 | -147.3%#14 | -343.6%#4 | -15.5%#6 | -36.7%#2 | — | 128.6%#10 | — |
| MRNA | $61.8B#1 | — | 9.1x#8 | 31.8x#2 | -39.9%#6 | 20.8%#5 | -158.1%#3 | -41.7%#12 | -54.6%#4 | — | 507.6%#4 | — |
| TWST | $10.1B#3 | — | 22.6x#13 | 26.8x#1 | 20.3%#4 | 62.8%#1 | -36.2%#1 | -17.4%#8 | -41.4%#3 | — | 474.7%#5 | — |
| ORKA | $6.3B#11 | — | 5.7x#3 | — | — | -25.9%#7 | — | -9.5%#4 | — | — | 474.1%#6 | — |
| KYMR | $9.8B#4 | — | 6.5x#6 | 250.4x#6 | -16.7%#5 | 39.1%#2 | -891.1%#6 | 20.6%#1 | — | — | 130.9%#9 | — |
| VKTX | $3.4B#14 | — | 8.3x#7 | — | — | -227.1%#15 | — | -88.1%#14 | — | — | 11.0%#14 | — |
| PRAX | $8.4B#8 | — | 6.3x#4 | — | -100.0%#9 | -65.6%#10 | — | -22.6%#10 | — | — | 568.8%#3 | — |
| ERAS | $5.2B#13 | — | 14.5x#10 | — | — | 23.0%#4 | — | -34.4%#11 | — | — | 701.1%#1 | — |
| RVMD | $41.1B#2 | — | 15.8x#11 | — | — | -88.5%#12 | — | -43.4%#13 | — | — | 323.6%#7 | — |
| RYTM | $6.7B#9 | — | 65.2x#14 | 35.4x#3 | 45.8%#3 | 24.6%#3 | -101.2%#2 | -0.2%#3 | -133.8%#5 | — | -1.0%#15 | — |
| CGON | $6.5B#10 | — | 6.3x#5 | 1610.6x#7 | 254.7%#2 | -82.9%#11 | -4722.1%#7 | -15.6%#7 | -18.8%#1 | — | 89.1%#11 | — |
| SLS | $2.3B#15 | — | 16.8x#12 | — | -100.0%#9 | 13.0%#6 | — | -19.5%#9 | — | — | 611.5%#2 | — |
| PCVX | $8.8B#7 | — | 3.2x#1 | — | — | -65.2%#9 | — | -0.0%#2 | — | — | 80.9%#12 | — |
| DNTH | $5.7B#12 | — | 4.8x#2 | 2787.4x#8 | -67.3%#7 | -91.1%#13 | -8739.3%#8 | -13.9%#5 | — | — | 161.1%#8 | — |
| CYTK | $9.6B#5 | — | — | 108.9x#4 | 376.6%#1 | -33.2%#8 | -695.4%#5 | — | — | — | 39.7%#13 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-18。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议